
---
title: 'MIT新药物组合显示出早期治疗胰腺癌的潜力'
categories: 
 - 新媒体
 - 科学网
 - 博客
headimg: 'https://cors.zfour.workers.dev/?http://bbs.sciencenet.cn/home.php?mod=attachment&filename=image.png&id=761333'
author: 科学网
comments: false
date: Fri, 06 Aug 2021 16:06:00 GMT
thumbnail: 'https://cors.zfour.workers.dev/?http://bbs.sciencenet.cn/home.php?mod=attachment&filename=image.png&id=761333'
---

<div>   
<p style="line-height: 2em;"><span style="font-size: 24px; font-family: "arial black", "avant garde";">MIT</span><span style="font-size: 24px; font-family: 黑体, SimHei;">新药物组合显示出早期治疗胰腺癌的潜力</span></p><p style="line-height: 2em;"><span style="font-size: 18px; font-family: "times new roman";">诸平</span></p><p style="line-height: 2em;"><span style="font-size: 18px; font-family: "times new roman";"><img src="https://cors.zfour.workers.dev/?http://bbs.sciencenet.cn/home.php?mod=attachment&filename=image.png&id=761333" title alt="image.png" referrerpolicy="no-referrer"> </span></p><p style="line-height: 2em;"><span style="font-size: 18px; font-family: "times new roman";">Caption: <a href="https://news.mit.edu/2021/pancreatic-cancer-immunotherapy-cd155-0805" target="_self">In this pancreatic tumor, T cells (pink) have infiltrated tumor cells (labeled green) following treatment with a novel combination immunotherapy developed by MIT researchers. Credit: William Freed-Pastor</a></span></p><p style="line-height: 2em;"><span style="font-size: 18px; font-family: "times new roman";">据美国麻省理工学院（</span><a href="http://web.mit.edu/" target="_blank" style="text-decoration: underline; font-size: 18px; font-family: "times new roman";"><span style="font-size: 18px; font-family: "times new roman";">Massachusetts Institute of Technology</span></a><span style="font-size: 18px; font-family: "times new roman";"><span style="font-size: 18px; font-family: 宋体;">简称</span>MIT<span style="font-size: 18px; font-family: 宋体;">）</span>2021<span style="font-size: 18px; font-family: 宋体;">年</span>8<span style="font-size: 18px; font-family: 宋体;">月</span>5<span style="font-size: 18px; font-family: 宋体;">日提供的消息，美国</span>MIT<span style="font-size: 18px; font-family: 宋体;">大卫·科赫综合癌症研究所</span>(David H. Koch Institute for Integrative Cancer Research, MIT)<span style="font-size: 18px; font-family: 宋体;">、美国哈佛医学院德纳</span>-<span style="font-size: 18px; font-family: 宋体;">法伯癌症研究所（</span>Dana-Farber Cancer Institute, Harvard Medical School<span style="font-size: 18px; font-family: 宋体;">）、</span>MIT<span style="font-size: 18px; font-family: 宋体;">生物学系、麻省总医院（</span>Massachusetts General Hospital<span style="font-size: 18px; font-family: 宋体;">）、麻省理工学院和哈佛大学的布罗德研究所（</span>Broad Institute of MIT and Harvard<span style="font-size: 18px; font-family: 宋体;">）、哈佛医学院布里格姆妇女医院（</span>Brigham and Women's Hospital, Harvard Medical School<span style="font-size: 18px; font-family: 宋体;">）以及美国西雅图（</span>Seattle<span style="font-size: 18px; font-family: 宋体;">）的</span>NanoString Inc.<span style="font-size: 18px; font-family: 宋体;">的研究人员合作研究发现，新药物组合显示出早期治疗胰腺癌的潜力（</span><a href="https://news.mit.edu/2021/pancreatic-cancer-immunotherapy-cd155-0805" target="_self">New drug combo shows early potential for treating pancreatic cancer</a><span style="font-size: 18px; font-family: 宋体;">）。</span></span></p><p style="line-height: 2em;"><span style="font-size: 18px; font-family: "times new roman";"><span style="font-size: 18px; font-family: 宋体;">胰腺癌（</span>Pancreatic cancer<span style="font-size: 18px; font-family: 宋体;">）是最致命的癌症之一，每年约有</span>6<span style="font-size: 18px; font-family: 宋体;">万美国人患此病。且确诊后，只有不到</span>10%<span style="font-size: 18px; font-family: 宋体;">的患者能存活</span>5<span style="font-size: 18px; font-family: 宋体;">年。</span></span></p><p style="line-height: 2em;"><span style="font-size: 18px; font-family: "times new roman";"><span style="font-size: 18px; font-family: 宋体;">虽然一些化疗（</span>chemotherapies<span style="font-size: 18px; font-family: 宋体;">）最初是有效的，但胰腺肿瘤（</span></span><a href="https://medicalxpress.com/tags/pancreatic+tumors/" style="text-decoration: underline; font-size: 18px; font-family: "times new roman";" target="_blank"><span style="font-size: 18px; font-family: "times new roman";">pancreatic tumors</span></a><span style="font-size: 18px; font-family: "times new roman";"><span style="font-size: 18px; font-family: 宋体;">）经常变得对化疗产生抵抗力。这种疾病也被证明很难用免疫疗法（</span>immunotherapy<span style="font-size: 18px; font-family: 宋体;">）等新方法治疗。然而，麻省理工学院（</span>MIT<span style="font-size: 18px; font-family: 宋体;">）的一组研究人员现在已经开发出一种免疫治疗策略（</span>immunotherapy strategy<span style="font-size: 18px; font-family: 宋体;">），并证明它可以消除小鼠的胰腺肿瘤。这种新疗法结合了三种药物，帮助增强人体自身对肿瘤的免疫防御，预计将在今年晚些时候进入临床试验。</span></span></p><p style="line-height: 2em;"><span style="font-size: 18px; font-family: "times new roman";"><span style="font-size: 18px; font-family: 宋体;">麻省理工学院科赫综合癌症研究所（</span><a href="https://news.mit.edu/2021/pancreatic-cancer-immunotherapy-cd155-0805" target="_self">MIT's Koch Institute for Integrative Cancer Research</a><span style="font-size: 18px; font-family: 宋体;">）高级博士后威廉·弗雷德</span>-<span style="font-size: 18px; font-family: 宋体;">帕斯特（</span>William Freed-Pastor<span style="font-size: 18px; font-family: 宋体;">）说：“对于胰腺癌的治疗，我们没有很多好的选择，这在临床上是一种毁灭性的疾病。如果这种方法能在患者身上产生持久的反应，它将对至少一部分患者的生活产生重大影响，但我们需要看到它在试验中的实际表现。”</span></span></p><p style="line-height: 2em;"><span style="font-size: 18px; font-family: "times new roman";"><span style="font-size: 18px; font-family: 宋体;">威廉·弗雷德</span>-<span style="font-size: 18px; font-family: 宋体;">帕斯特是丹娜</span>-<span style="font-size: 18px; font-family: 宋体;">法伯癌症研究所（</span><a href="https://news.mit.edu/2021/pancreatic-cancer-immunotherapy-cd155-0805" target="_self">Dana-Farber Cancer Institute</a><span style="font-size: 18px; font-family: 宋体;">）的一位医学肿瘤学家，他也是这项新研究的第一作者，这项研究发表于</span>2021<span style="font-size: 18px; font-family: 宋体;">年</span>8<span style="font-size: 18px; font-family: 宋体;">月</span>5<span style="font-size: 18px; font-family: 宋体;">日已经在《癌细胞》（</span>Cancer Cell<span style="font-size: 18px; font-family: 宋体;">）杂志网站发表——</span></span><a href="https://www.sciencedirect.com/science/article/abs/pii/S1535610821003846?via%3Dihub#!" style="text-decoration: underline; font-size: 18px; font-family: "times new roman";" target="_blank"><span style="font-size: 18px; font-family: "times new roman";">William A. Freed-Pastor,</span></a><span style="font-size: 18px; font-family: "times new roman";"> </span><a href="https://www.sciencedirect.com/science/article/abs/pii/S1535610821003846?via%3Dihub#!" style="text-decoration: underline; font-size: 18px; font-family: "times new roman";" target="_blank"><span style="font-size: 18px; font-family: "times new roman";">Laurens J. Lambert,</span></a><span style="font-size: 18px; font-family: "times new roman";"> </span><a href="https://www.sciencedirect.com/science/article/abs/pii/S1535610821003846?via%3Dihub#!" style="text-decoration: underline; font-size: 18px; font-family: "times new roman";" target="_blank"><span style="font-size: 18px; font-family: "times new roman";">Zackery A. Ely,</span></a><span style="font-size: 18px; font-family: "times new roman";"> </span><a href="https://www.sciencedirect.com/science/article/abs/pii/S1535610821003846?via%3Dihub#!" style="text-decoration: underline; font-size: 18px; font-family: "times new roman";" target="_blank"><span style="font-size: 18px; font-family: "times new roman";">Nimisha B. Pattada, </span></a><a href="https://www.sciencedirect.com/science/article/abs/pii/S1535610821003846?via%3Dihub#!" style="text-decoration: underline; font-size: 18px; font-family: "times new roman";" target="_blank"><span style="font-size: 18px; font-family: "times new roman";">Arjun Bhutkar, </span></a><a href="https://www.sciencedirect.com/science/article/abs/pii/S1535610821003846?via%3Dihub#!" style="text-decoration: underline; font-size: 18px; font-family: "times new roman";" target="_blank"><span style="font-size: 18px; font-family: "times new roman";">George Eng, </span></a><a href="https://www.sciencedirect.com/science/article/abs/pii/S1535610821003846?via%3Dihub#!" style="text-decoration: underline; font-size: 18px; font-family: "times new roman";" target="_blank"><span style="font-size: 18px; font-family: "times new roman";">Kim L. Mercer, </span></a><a href="https://www.sciencedirect.com/science/article/abs/pii/S1535610821003846?via%3Dihub#!" style="text-decoration: underline; font-size: 18px; font-family: "times new roman";" target="_blank"><span style="font-size: 18px; font-family: "times new roman";">Ana P. Garcia, </span></a><a href="https://www.sciencedirect.com/science/article/abs/pii/S1535610821003846?via%3Dihub#!" style="text-decoration: underline; font-size: 18px; font-family: "times new roman";" target="_blank"><span style="font-size: 18px; font-family: "times new roman";">Lin Lin,</span></a><span style="font-size: 18px; font-family: "times new roman";"> </span><a href="https://www.sciencedirect.com/science/article/abs/pii/S1535610821003846?via%3Dihub#!" style="text-decoration: underline; font-size: 18px; font-family: "times new roman";" target="_blank"><span style="font-size: 18px; font-family: "times new roman";">William M. Rideout III,</span></a><span style="font-size: 18px; font-family: "times new roman";"> </span><a href="https://www.sciencedirect.com/science/article/abs/pii/S1535610821003846?via%3Dihub#!" style="text-decoration: underline; font-size: 18px; font-family: "times new roman";" target="_blank"><span style="font-size: 18px; font-family: "times new roman";">William L.Hwang,</span></a><span style="font-size: 18px; font-family: "times new roman";"> </span><a href="https://www.sciencedirect.com/science/article/abs/pii/S1535610821003846?via%3Dihub#!" style="text-decoration: underline; font-size: 18px; font-family: "times new roman";" target="_blank"><span style="font-size: 18px; font-family: "times new roman";">Jason M. Schenkel,</span></a><span style="font-size: 18px; font-family: "times new roman";"> </span><a href="https://www.sciencedirect.com/science/article/abs/pii/S1535610821003846?via%3Dihub#!" style="text-decoration: underline; font-size: 18px; font-family: "times new roman";" target="_blank"><span style="font-size: 18px; font-family: "times new roman";">Alex M. Jaeger</span></a><span style="font-size: 18px; font-family: "times new roman";">, </span><a href="https://www.sciencedirect.com/science/article/abs/pii/S1535610821003846?via%3Dihub#!" style="text-decoration: underline; font-size: 18px; font-family: "times new roman";" target="_blank"><span style="font-size: 18px; font-family: "times new roman";">Roderick T. Bronson,</span></a><span style="font-size: 18px; font-family: "times new roman";"> </span><a href="https://www.sciencedirect.com/science/article/abs/pii/S1535610821003846?via%3Dihub#!" style="text-decoration: underline; font-size: 18px; font-family: "times new roman";" target="_blank"><span style="font-size: 18px; font-family: "times new roman";">Peter M. K. Westcott</span></a><span style="font-size: 18px; font-family: "times new roman";">, </span><a href="https://www.sciencedirect.com/science/article/abs/pii/S1535610821003846?via%3Dihub#!" style="text-decoration: underline; font-size: 18px; font-family: "times new roman";" target="_blank"><span style="font-size: 18px; font-family: "times new roman";">Tyler D. Hether,</span></a><a href="https://www.sciencedirect.com/science/article/abs/pii/S1535610821003846?via%3Dihub#!" style="text-decoration: underline; font-size: 18px; font-family: "times new roman";" target="_blank"><span style="font-size: 18px; font-family: "times new roman";">Prajan Divakar,</span></a><a href="https://www.sciencedirect.com/science/article/abs/pii/S1535610821003846?via%3Dihub#!" style="text-decoration: underline; font-size: 18px; font-family: "times new roman";" target="_blank"><span style="font-size: 18px; font-family: "times new roman";">Jason W. Reeves,</span></a><a href="https://www.sciencedirect.com/science/article/abs/pii/S1535610821003846?via%3Dihub#!" style="text-decoration: underline; font-size: 18px; font-family: "times new roman";" target="_blank"><span style="font-size: 18px; font-family: "times new roman";">Vikram Deshpande, </span></a><a href="https://www.sciencedirect.com/science/article/abs/pii/S1535610821003846?via%3Dihub#!" style="text-decoration: underline; font-size: 18px; font-family: "times new roman";" target="_blank"><span style="font-size: 18px; font-family: "times new roman";">Toni Delorey, </span></a><a href="https://www.sciencedirect.com/science/article/abs/pii/S1535610821003846?via%3Dihub#!" style="text-decoration: underline; font-size: 18px; font-family: "times new roman";" target="_blank"><span style="font-size: 18px; font-family: "times new roman";">Devan Phillips, </span></a><a href="https://www.sciencedirect.com/science/article/abs/pii/S1535610821003846?via%3Dihub#!" style="text-decoration: underline; font-size: 18px; font-family: "times new roman";" target="_blank"><span style="font-size: 18px; font-family: "times new roman";">Omer H. Yilmaz,</span></a><span style="font-size: 18px; font-family: "times new roman";"> </span><a href="https://www.sciencedirect.com/science/article/abs/pii/S1535610821003846?via%3Dihub#!" style="text-decoration: underline; font-size: 18px; font-family: "times new roman";" target="_blank"><span style="font-size: 18px; font-family: "times new roman";">Aviv Regev,</span></a><span style="font-size: 18px; font-family: "times new roman";"> </span><a href="https://www.sciencedirect.com/science/article/abs/pii/S1535610821003846?via%3Dihub#!" style="text-decoration: underline; font-size: 18px; font-family: "times new roman";" target="_blank"><span style="font-size: 18px; font-family: "times new roman";">Tyler Jacks</span></a><span style="font-size: 18px; font-family: "times new roman";">. The CD155/TIGIT axis promotes and maintains immune evasion in neoantigen-expressing pancreatic cancer. </span><a href="https://medicalxpress.com/journals/cancer-cell/" style="text-decoration: underline; font-size: 18px; font-family: "times new roman";" target="_blank"><span style="font-size: 18px; font-family: "times new roman";">Cancer Cell</span></a><span style="font-size: 18px; font-family: "times new roman";">, Published: August 5, 2021. </span><a href="http://dx.doi.org/10.1016/j.ccell.2021.07.007" target="_blank" style="text-decoration: underline; font-size: 18px; font-family: "times new roman";"><span style="font-size: 18px; font-family: "times new roman";">DOI: 10.1016/j.ccell.2021.07.007</span></a><span style="font-size: 18px; font-family: "times new roman";">. </span><a href="https://doi.org/10.1016/j.ccell.2021.07.007" target="_blank" title="Persistent link using digital object identifier" style="text-decoration: underline; font-size: 18px; font-family: "times new roman";"><span style="font-size: 18px; font-family: "times new roman";">https://doi.org/10.1016/j.ccell.2021.07.007</span></a></p><p style="line-height: 2em;"><span style="font-size: 18px; font-family: "times new roman";"><span style="font-size: 18px; font-family: 宋体;">大卫·科赫生物学教授（</span>David H. Koch Professor of Biology<span style="font-size: 18px; font-family: 宋体;">）、科赫研究所（</span>Koch Institute<span style="font-size: 18px; font-family: 宋体;">）成员泰勒·杰克斯</span>(Tyler Jacks)<span style="font-size: 18px; font-family: 宋体;">是这篇论文的通讯作者。</span></span></p><p style="line-height: 2em;"><span style="font-size: 18px; font-family: "times new roman";"><strong><span style="font-size: 18px; font-family: 宋体;">免疫攻击（</span><a href="https://doi.org/10.1016/j.ccell.2021.07.007" target="_blank">Immune attack</a></strong><strong><span style="font-size: 18px; font-family: 宋体;">）</span></strong></span></p><p style="line-height: 2em;"><span style="font-size: 18px; font-family: "times new roman";"><span style="font-size: 18px; font-family: 宋体;">人体的免疫系统含有</span>T<span style="font-size: 18px; font-family: 宋体;">细胞，它们可以识别并摧毁表达癌蛋白的细胞，但大多数肿瘤会产生一种高度免疫抑制的环境（</span><a href="https://news.mit.edu/2021/pancreatic-cancer-immunotherapy-cd155-0805" target="_self">immunosuppressive environment</a><span style="font-size: 18px; font-family: 宋体;">），使这些</span>T<span style="font-size: 18px; font-family: 宋体;">细胞失效，从而帮助肿瘤存活。</span></span></p><p style="line-height: 2em;"><span style="font-size: 18px; font-family: "times new roman";"><span style="font-size: 18px; font-family: 宋体;">免疫检查点疗法</span>(Immune checkpoint therapy)<span style="font-size: 18px; font-family: 宋体;">是目前临床使用的最常见的免疫疗法。它的工作原理是去除这些</span>T<span style="font-size: 18px; font-family: 宋体;">细胞上的“紧箍咒”</span> <span style="font-size: 18px; font-family: 宋体;">（</span>removing the brakes on these T cells<span style="font-size: 18px; font-family: 宋体;">），使它们恢复活力，从而摧毁肿瘤。有一类免疫治疗药物已经在治疗多种癌症方面取得了成功，它针对的是</span>PD-L1(<span style="font-size: 18px; font-family: 宋体;">一种关闭</span>T<span style="font-size: 18px; font-family: 宋体;">细胞的癌症相关蛋白</span>)<span style="font-size: 18px; font-family: 宋体;">和</span>PD-1(<span style="font-size: 18px; font-family: 宋体;">一种</span>PD-L1<span style="font-size: 18px; font-family: 宋体;">结合的</span>T<span style="font-size: 18px; font-family: 宋体;">细胞蛋白</span>)<span style="font-size: 18px; font-family: 宋体;">之间的相互作用。阻断</span>PD-L1<span style="font-size: 18px; font-family: 宋体;">或</span>PD-1<span style="font-size: 18px; font-family: 宋体;">的药物，也被称为检查点抑制剂（</span>checkpoint inhibitors<span style="font-size: 18px; font-family: 宋体;">），已经被批准用于治疗黑色素瘤（</span>melanoma<span style="font-size: 18px; font-family: 宋体;">）和肺癌（</span>lung cancer<span style="font-size: 18px; font-family: 宋体;">）等癌症，但它们对胰腺肿瘤（</span>pancreatic tumors<span style="font-size: 18px; font-family: 宋体;">）的效果非常小。</span></span></p><p style="line-height: 2em;"><span style="font-size: 18px; font-family: "times new roman";"><span style="font-size: 18px; font-family: 宋体;">一些研究人员假设，这种失败可能是由于胰腺肿瘤不表达那么多的癌蛋白，即新抗原（</span>neoantigens<span style="font-size: 18px; font-family: 宋体;">）。这将减少</span>T<span style="font-size: 18px; font-family: 宋体;">细胞的攻击目标，因此即使</span>T<span style="font-size: 18px; font-family: 宋体;">细胞受到检查点抑制剂的刺激，它们也无法识别和摧毁肿瘤细胞。</span></span></p><p style="line-height: 2em;"><span style="font-size: 18px; font-family: "times new roman";"><span style="font-size: 18px; font-family: 宋体;">然而，最近的一些研究表明，而且麻省理工学院的新研究也证实，许多胰腺肿瘤实际上确实表达癌症特异性新抗原（</span>cancer-specific neoantigens<span style="font-size: 18px; font-family: 宋体;">）。这一发现让研究人员怀疑，可能是一种不同类型的制动，而不是</span>PD-1/PD-L1<span style="font-size: 18px; font-family: 宋体;">系统，使胰腺癌患者（</span></span><a href="https://medicalxpress.com/tags/pancreatic+cancer/" style="text-decoration: underline; font-size: 18px; font-family: "times new roman";" target="_blank"><span style="font-size: 18px; font-family: "times new roman";">pancreatic cancer</span></a><span style="font-size: 18px; font-family: "times new roman";"> patients<span style="font-size: 18px; font-family: 宋体;">）的</span>T<span style="font-size: 18px; font-family: 宋体;">细胞丧失功能。</span></span></p><p style="line-height: 2em;"><span style="font-size: 18px; font-family: "times new roman";"><span style="font-size: 18px; font-family: 宋体;">在一项使用小鼠胰腺癌模型的研究中，研究人员发现，事实上</span>PD-L1<span style="font-size: 18px; font-family: 宋体;">在胰腺癌细胞上并不高表达。相反，大多数胰腺癌细胞表达一种叫做</span>CD155<span style="font-size: 18px; font-family: 宋体;">的蛋白质，它激活</span>T<span style="font-size: 18px; font-family: 宋体;">细胞上一种叫做</span>TIGIT<span style="font-size: 18px; font-family: 宋体;">的受体。</span></span></p><p style="line-height: 2em;"><span style="font-size: 18px; font-family: "times new roman";"><span style="font-size: 18px; font-family: 宋体;">当</span>TIGIT<span style="font-size: 18px; font-family: 宋体;">被激活时，</span>T<span style="font-size: 18px; font-family: 宋体;">细胞进入一种被称为“</span>T<span style="font-size: 18px; font-family: 宋体;">细胞衰竭（</span>T cell exhaustion<span style="font-size: 18px; font-family: 宋体;">）”的状态，在这种状态下，它们无法攻击胰腺肿瘤细胞。在对胰腺癌患者肿瘤的分析中，研究人员观察到大约</span>60%<span style="font-size: 18px; font-family: 宋体;">的患者</span>TIGIT<span style="font-size: 18px; font-family: 宋体;">表达和</span>T<span style="font-size: 18px; font-family: 宋体;">细胞衰竭，他们还发现患者肿瘤细胞中</span>CD155<span style="font-size: 18px; font-family: 宋体;">的水平很高。</span></span></p><p style="line-height: 2em;"><span style="font-size: 18px; font-family: "times new roman";"><span style="font-size: 18px; font-family: 宋体;">威廉·弗雷德</span>-<span style="font-size: 18px; font-family: 宋体;">帕斯特说：“</span>CD155/TIGIT<span style="font-size: 18px; font-family: 宋体;">轴（</span>CD155/TIGIT axis<span style="font-size: 18px; font-family: 宋体;">）的功能与更著名的</span>PD-L1/PD-1<span style="font-size: 18px; font-family: 宋体;">轴（</span>PD-L1/PD-1 axis<span style="font-size: 18px; font-family: 宋体;">）非常相似。</span>TIGIT<span style="font-size: 18px; font-family: 宋体;">在</span>T<span style="font-size: 18px; font-family: 宋体;">细胞上表达，并作为这些</span>T<span style="font-size: 18px; font-family: 宋体;">细胞的刹车。当</span>TIGIT<span style="font-size: 18px; font-family: 宋体;">阳性</span>T<span style="font-size: 18px; font-family: 宋体;">细胞（</span>TIGIT-positive T cell<span style="font-size: 18px; font-family: 宋体;">）遇到任何表达高水平</span>CD155<span style="font-size: 18px; font-family: 宋体;">的细胞时，它基本上可以关闭该</span>T<span style="font-size: 18px; font-family: 宋体;">细胞。”</span></span></p><p style="line-height: 2em;"><span style="font-size: 18px; font-family: "times new roman";"><strong><span style="font-size: 18px; font-family: 宋体;">联合用药（</span><a href="https://doi.org/10.1016/j.ccell.2021.07.007" target="_blank">Drug combination</a></strong><strong><span style="font-size: 18px; font-family: 宋体;">）</span></strong></span></p><p style="line-height: 2em;"><span style="font-size: 18px; font-family: "times new roman";"><span style="font-size: 18px; font-family: 宋体;">然后，研究人员开始研究，他们是否可以利用这些知识来恢复疲惫的</span>T<span style="font-size: 18px; font-family: 宋体;">细胞的活力，并刺激它们攻击胰腺肿瘤细胞。他们测试了多种抑制</span>PD-1<span style="font-size: 18px; font-family: 宋体;">和</span>TIGIT<span style="font-size: 18px; font-family: 宋体;">的实验药物组合，以及另一种被称为</span>CD40<span style="font-size: 18px; font-family: 宋体;">激动剂抗体（</span>CD40 agonist antibody<span style="font-size: 18px; font-family: 宋体;">）的药物。</span></span></p><p style="line-height: 2em;"><span style="font-size: 18px; font-family: "times new roman";">CD40<span style="font-size: 18px; font-family: 宋体;">激动剂抗体（</span>CD40 agonist antibodies<span style="font-size: 18px; font-family: 宋体;">）是一些能激活</span>T<span style="font-size: 18px; font-family: 宋体;">细胞并将它们驱入肿瘤的药物，目前正在临床评估其中一些抗体用于治疗胰腺癌。在小鼠动物实验中，麻省理工学院的研究小组发现，治疗</span>PD-1<span style="font-size: 18px; font-family: 宋体;">的药物本身几乎没有效果，就像之前治疗胰腺癌所显示的那样。他们还发现，</span>CD40<span style="font-size: 18px; font-family: 宋体;">激动剂抗体与</span>PD-1<span style="font-size: 18px; font-family: 宋体;">抑制剂或</span>TIGIT<span style="font-size: 18px; font-family: 宋体;">抑制剂结合，能够阻止一些动物的肿瘤生长，但未出现肿瘤实质性地缩小。</span></span></p><p style="line-height: 2em;"><span style="font-size: 18px; font-family: "times new roman";"><span style="font-size: 18px; font-family: 宋体;">然而，当他们将</span>CD40<span style="font-size: 18px; font-family: 宋体;">激动剂抗体与</span>PD-1<span style="font-size: 18px; font-family: 宋体;">抑制剂和</span>TIGIT<span style="font-size: 18px; font-family: 宋体;">抑制剂结合时，他们发现了戏剧性的效果。在接受这种治疗的动物中，大约有一半的胰腺肿瘤缩小了，在</span>25%<span style="font-size: 18px; font-family: 宋体;">的实验小鼠中，肿瘤完全消失了！而且，在停止治疗后，肿瘤没有再生长即无复发。威廉·弗雷德</span>-<span style="font-size: 18px; font-family: 宋体;">帕斯特说：“我们显然对此非常兴奋！”</span></span></p><p style="line-height: 2em;"><span style="font-size: 18px; font-family: "times new roman";"><span style="font-size: 18px; font-family: 宋体;">麻省理工学院的团队与卢斯特加尔滕胰腺癌研究基金会（</span>Lustgarten Foundation for Pancreatic Cancer Research<span style="font-size: 18px; font-family: 宋体;">）合作，该基金会对此项研究提供了资助；麻省理工学院的团队找到了两家制药公司，他们在开发</span>PD-1<span style="font-size: 18px; font-family: 宋体;">抑制剂（</span>PD-1 inhibitor<span style="font-size: 18px; font-family: 宋体;">）、</span>TIGIT<span style="font-size: 18px; font-family: 宋体;">抑制剂（</span>TIGIT inhibitor<span style="font-size: 18px; font-family: 宋体;">）和</span>CD40<span style="font-size: 18px; font-family: 宋体;">激动剂抗体（</span>CD40 agonist antibody<span style="font-size: 18px; font-family: 宋体;">）。这些药物还没有获得美国食品药品管理局（</span>FDA<span style="font-size: 18px; font-family: 宋体;">）的批准，但它们都已经进入了</span>2<span style="font-size: 18px; font-family: 宋体;">期临床试验（</span>phase 2 </span><a href="https://medicalxpress.com/tags/clinical+trials/" style="text-decoration: underline; font-size: 18px; font-family: "times new roman";" target="_blank"><span style="font-size: 18px; font-family: "times new roman";">clinical trials</span></a><span style="font-size: 18px; font-family: "times new roman";">）。对这三种药物组合的临床试验预计将于今年晚些时候开始。</span></p><p style="line-height: 2em;"><span style="font-size: 18px; font-family: "times new roman";"><span style="font-size: 18px; font-family: 宋体;">泰勒·杰克斯说：“这项工作使用了高度复杂的基因工程小鼠模型来研究胰腺癌中免疫抑制的细节，结果指出了潜在的治疗这种毁灭性疾病——胰腺癌的新方法。我们正在尽快在患者身上测试这些疗法，并感谢卢斯特加尔滕胰腺癌研究基金会和</span>Stand Up to Cancer<span style="font-size: 18px; font-family: 宋体;">基金会对这项研究的支持。”</span></span></p><p style="line-height: 2em;"><span style="font-size: 18px; font-family: "times new roman";"><span style="font-size: 18px; font-family: 宋体;">在进行临床试验的同时，麻省理工学院的研究小组计划分析哪种类型的胰腺肿瘤对这种药物组合反应最好。他们还在做进一步的动物研究，看看他们是否能提高治疗的有效性，超过他们在这项研究中看到的</span>50%<span style="font-size: 18px; font-family: 宋体;">。</span></span></p><p style="line-height: 2em;"><span style="font-size: 18px; font-family: "times new roman";"><span style="font-size: 18px; font-family: 宋体;">除了卢斯特加尔滕胰腺癌研究基金会，这项研究还得到了</span>Stand Up to Cancer<span style="font-size: 18px; font-family: 宋体;">、霍华德</span>·<span style="font-size: 18px; font-family: 宋体;">休斯医学研究所（</span>Howard Hughes Medical Institute<span style="font-size: 18px; font-family: 宋体;">）、丹娜</span>-<span style="font-size: 18px; font-family: 宋体;">法伯</span>/<span style="font-size: 18px; font-family: 宋体;">哈佛大学癌症中心（</span>Dana-Farber/Harvard Cancer Center<span style="font-size: 18px; font-family: 宋体;">）、达蒙·鲁尼恩癌症研究基金会（</span>Damon Runyon Cancer research Foundation<span style="font-size: 18px; font-family: 宋体;">）和美国国家卫生研究院（</span>National Institutes of Health<span style="font-size: 18px; font-family: 宋体;">）的资助。</span></span></p><p style="line-height: 2em;"><span style="font-size: 18px; font-family: "times new roman";">上述介绍，仅供参考。欲了解更多信息敬请注意浏览<a href="https://doi.org/10.1016/j.ccell.2021.07.007" target="_blank">原文</a>或者<a href="https://news.mit.edu/2021/pancreatic-cancer-immunotherapy-cd155-0805" target="_self">相关报道</a>。</span></p><p style="line-height: 2em;"><a href="https://medicalxpress.com/news/2021-06-genetically-cells-pancreatic-cancer.html" style="text-decoration: underline; font-size: 18px; font-family: "times new roman";" target="_blank"><span style="font-size: 18px; font-family: "times new roman";">Using genetically engineered T cells to fight pancreatic cancer</span></a></p><p style="line-height: 2em;"><a href="https://doi.org/10.1016/j.ccell.2021.07.007" target="_blank" style="font-size: 18px; font-family: "arial black", "avant garde"; text-decoration: underline;"><span style="font-size: 18px; font-family: "arial black", "avant garde";">Highlights</span></a></p><p style="line-height: 2em;"><span style="font-size: 18px; font-family: "times new roman";">• A subset of neoantigen-expressing pancreas cancer evades immune surveillance</span></p><p style="line-height: 2em;"><span style="font-size: 18px; font-family: "times new roman";">• Markers of T cell exhaustion typify pancreas cancer tumor-infiltrating lymphocytes</span></p><p style="line-height: 2em;"><span style="font-size: 18px; font-family: "times new roman";">• The CD155/TIGIT axis promotes immune evasion in pancreas cancer</span></p><p style="line-height: 2em;"><span style="font-size: 18px; font-family: "times new roman";">• TIGIT/PD-1 co-blockade plus CD40 agonism reinvigorates tumor-reactive T cells</span></p><p style="line-height: 2em;"><a href="https://doi.org/10.1016/j.ccell.2021.07.007" target="_blank" style="font-size: 18px; font-family: "arial black", "avant garde"; text-decoration: underline;"><span style="font-size: 18px; font-family: "arial black", "avant garde";">Summary</span></a></p><p style="line-height: 2em;"><span style="font-size: 18px; font-family: "times new roman";">The CD155/TIGIT axis can be co-opted during immune evasion in chronic viral infections and cancer. </span><a href="https://www.sciencedirect.com/topics/medicine-and-dentistry/pancreas-adenocarcinoma" title="Learn more about Pancreatic adenocarcinoma from ScienceDirect's AI-generated Topic Pages" style="text-decoration: underline; font-size: 18px; font-family: "times new roman";" target="_blank"><span style="font-size: 18px; font-family: "times new roman";">Pancreatic adenocarcinoma</span></a><span style="font-size: 18px; font-family: "times new roman";"> (PDAC) is a highly lethal malignancy, and immune-based strategies to combat this disease have been largely unsuccessful to date. We corroborate prior reports that a substantial portion of </span><a href="https://www.sciencedirect.com/topics/medicine-and-dentistry/pancreatic-ductal-adenocarcinoma" title="Learn more about PDAC from ScienceDirect's AI-generated Topic Pages" style="text-decoration: underline; font-size: 18px; font-family: "times new roman";" target="_blank"><span style="font-size: 18px; font-family: "times new roman";">PDAC</span></a><span style="font-size: 18px; font-family: "times new roman";"> harbors predicted high-affinity MHC class I-restricted neoepitopes and extend these findings to advanced/metastatic disease. Using multiple preclinical models of neoantigen-expressing PDAC, we demonstrate that intratumoral neoantigen-specific CD8+ T cells adopt multiple states of dysfunction, resembling those in tumor-infiltrating lymphocytes of PDAC patients. Mechanistically, genetic and/or pharmacologic modulation of the CD155/TIGIT axis was sufficient to promote immune evasion in autochthonous neoantigen-expressing PDAC. Finally, we demonstrate that the CD155/TIGIT axis is critical in maintaining immune evasion in PDAC and uncover a combination </span><a href="https://www.sciencedirect.com/topics/medicine-and-dentistry/immunotherapy" title="Learn more about immunotherapy from ScienceDirect's AI-generated Topic Pages" style="text-decoration: underline; font-size: 18px; font-family: "times new roman";" target="_blank"><span style="font-size: 18px; font-family: "times new roman";">immunotherapy</span></a><span style="font-size: 18px; font-family: "times new roman";"> (TIGIT/PD-1 co-blockade plus CD40 agonism) that elicits profound anti-tumor responses in preclinical models, now poised for clinical evaluation.</span></p><p style="line-height: 2em;"><span style="font-size: 18px; font-family: "times new roman";">Graphical abstract（在整理之中，==）</span></p><p><br></p>                    <br><br>
                                        <label style="font-size:13px; color:#850f0f">转载本文请联系原作者获取授权，同时请注明本文来自诸平科学网博客。<br>链接地址：</label><a href="http://blog.sciencenet.cn/blog-212210-1298627.html" target="_blank" style="font-size:13px; color:#850f0f">http://blog.sciencenet.cn/blog-212210-1298627.html </a>
  <br><br>上一篇：<a href="http://blog.sciencenet.cn/blog-212210-1298507.html" target="_black">Dimensions数据库收录咸阳师院作者论文究竟来自何刊</a><br>                    <!--大赛结束-->
                                        
  
</div>
            